可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]King DE,Egan BM,Mainous AG 3rd,et al.Elevation of C-reactive protein in people with prehypertension[J].J Clin Hypertens(Greenwich),2004,6(10):562-568.
[2]Bautista LE.Inflammation,endothelial dysfunction,and the risk of high blood pressure:epidemiologic and biological evidence[J].J Hum Hypertens,2003,17(4):223-230.
[3]Stuveling EM,Hillege HL, Bakker SJ,et al.C-reactive protein is associated with renal function abnormalities in a non-diabetic population[J].Kidney Int,2003,63(2):654-661.
[4]王国芳,张建立,倪秋杰,等.超声多普勒肾血流测定对1期高血压肾损害的研究[J].中国超声诊断杂志,2002,3(9):687-688.
[5]胡庆鹰,崔 炜,吴格日勒,等.彩色多普勒超声检查肾动脉阻力指数、搏动指数的研究进展[J].影像与介入,2009,23(6):76-77.
[6]李建初,姜玉新.肾动脉狭窄的彩色多普勒超声诊断[J].中国医学影像技术,2001,17(3):280-281.
[7]Afsar B,Ozdemir NF,Elsurer R,et al.Renal resistive index and nocturnal non-dipping:is there an associaton in essential hypertension?[J].Int Urol Nephrol,2009,41(2):383-391.
[8]Tedesco MA,Natale F,Mocerino R,et al.Renal resistive index and cardiovascular organ damage in a large population of hypertensive patients[J].J Hum Hypertens,2007,21(4):291-296.
[9]Pearson TA,Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease:application to clinical and public health practice:A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association[J].Circulation,2003,107(3):499-511.
[10]Bautista LE,López-Jaramillo P,Vera LM,et al.Is C-reactive protein an independent risk factor for essential hypertension?[J].J Hypertens,2001,19(5):857-861.
[11]Duygu H,Zoghi M,Nalbantgil S,et al.High sensitivity C-reactive protein may be an indicator of the development of atherosclerosis in myocardial bridging[J].Int J Cardiol,2008,124(2):267-270.
[12]Berni A,Ciani E,Bernetti M,et al.Renal resistive index and low-grade inflammation in patients with essential hypertension[J].J Hum Hypertens,2011 oct 13.doi:10.1038/jhh.2011.93.[Epub ahead of print]
[13]吴寿岭,高竟生,郝 冰,等.血清高敏C反应蛋白浓度与高血压病的相关性研究[J].中华心血管病杂志,2003,31(12):917-918.